Ixico
IXI · AIM · Health Care · mcap £17m · 7.8p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 01 Oct 26 | IXICO present PD research at radiology conference
IXICO to present advancements in neuroimaging for Parkinson’s disease at European radiology conference |
+0.0% | |
| 27 Jul 26 | Share option award
27 July 2026: IXICO plc (AIM: IXI), IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, today a |
+0.0% | |
| 15 Jul 26 | Director dealing | Director/PDMR Shareholding | |
| 13 Jul 26 | HD Industry Update
13 July 2026: IXICO plc (AIM: IXI), IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, notes t |
−10.8% | |
| 07 Jul 26 | Trading update | Trading Update
Revenue anticipated to be ahead of expectations for the year ending 30 September 2026 |
+12.0% |
| 19 Jun 26 | Routine | Exercise of Options | |
| 08 Jun 26 | Scientific advisors & partners update
IXICO EXPANDS RESEARCH COLLABORATIONS IN ALZHEIMER'S AND PARKINSON'S DISEASE |
+0.0% | |
| 22 May 26 | Company presentation at Mello 2026
22 May 2026, IXICO plc (AIM: IXI) - London, UK. |
+0.0% | |
| 21 May 26 | Contract win and contract extension
Alzheimer's contract win and Phase 2 clinical trial contract extension with total value of £1.3 million |
+1.8% | |
| 19 May 26 | Results | Half-year Results
Interim results for six months ending 31 March 2026 |
+27.8% |
| 12 May 26 | IXICO Updates AI Neuroimaging Platform
IXICO RELEASES LATEST VERSION OF AI-DRIVEN NEUROIMAGING TECHNOLOGY PLATFORM |
+1.9% | |
| 28 Apr 26 | Holding | Holding(s) in Company | |
| 28 Apr 26 | Holding | Holding(s) in Company | |
| 28 Apr 26 | Holding | Holding(s) in Company | |
| 28 Apr 26 | Holding | Holding(s) in Company | |
| 27 Apr 26 | Holding | Holding(s) in Company | |
| 27 Apr 26 | Holding | Holding(s) in Company | |
| 27 Apr 26 | Holding | Holding(s) in Company | |
| 27 Apr 26 | Holding | Holding(s) in Company | |
| 27 Apr 26 | Holding | Holding(s) in Company | |
| 24 Apr 26 | Holding | Holding(s) in Company | |
| 22 Apr 26 | Routine | Issue of Equity | |
| 21 Apr 26 | Trading update | Trading Update
Half-year Trading update and Notice of Interim Results |
+0.0% |
| 16 Apr 26 | Result of GM and Update on Issue of Equity
Result of General Meeting and Update on Issue of Equity |
−3.4% | |
| 07 Apr 26 | Fundraise | Result of Retail Offer
IXICO is pleased to announce that the Retail Offer launched on 31 March 2026 has now closed, raising gross proceeds of £30,320. |
−1.6% |
| 31 Mar 26 | Fundraise | Retail Offer
IXICO is pleased to announce a retail offer via the BookBuild Platform (the "Retail Offer") of up to 6,250,000 new ordinary shares ("Ordinary Shares") of £0.01 each in the capital of the Company (the "Retail Offer Shares |
+0.0% |
| 31 Mar 26 | Fundraise | Placings and Subscription
THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY. |
+0.0% |
| 26 Mar 26 | Collaboration with Medidata
IXICO and Medidata collaborate to create an advanced neuroimaging clinical trials platform |
+1.0% | |
| 26 Feb 26 | Validation of Neuroimaging Technology Platform
26 February 2026, IXICO plc (AIM: IXI) - London, UK. |
+0.0% | |
| 12 Feb 26 | C.£1.5 million Contract Extension
The following amendment has been made to the "c.£1.5 million Contract Extension" announcement released at 07:00 on 12 February 2026: |
−14.6% | |
| 12 Feb 26 | C.£1.5 million Contract Extension
c.£1.5 million contract extension on global Phase 2 clinical trial |
−14.6% | |
| 05 Feb 26 | Appointment of Chief Commercial Officer
IXICO appoints Chief Commercial Officer to accelerate business development activity and broaden US footprint |
+0.0% | |
| 23 Jan 26 | Result of AGM
IXICO plc (AIM: IXI), a global leader in neuroscience precision medicine and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announces that all resolutions pu |
−4.3% | |
| 09 Dec 25 | Share option award
9 December 2025 IXICO plc (AIM: IXI) - London, UK. |
+14.0% | |
| 09 Dec 25 | Results | Financial Results for year ended 30 September 2025
Financial Results for year ended 30 September 2025 and Notice of AGM |
+14.0% |
| 01 Dec 25 | Operational Update
IXICO strengthens Scientific Advisory Board with two prominent global Alzheimer's Disease and vascular experts |
+0.0% | |
| 27 Nov 25 | Notice of 2025 Full Year Results and IMC
Notice of 2025 Full Year Results and Investor Presentation |
+0.0% | |
| 17 Nov 25 | Clinical Trial Contract Win
Global Phase 3 clinical trial contract win worth over £3.5 million |
+4.7% | |
| 03 Nov 25 | Capital Markets Day Presentation and Video
03 November 2025 IXICO plc (AIM: IXI) - London, UK. |
+2.2% | |
| 16 Oct 25 | Trading update | Trading Update
Trading update for the year ended 30 September 2025 |
−2.0% |
| 15 Oct 25 | New contract win and contract extension
contract extension worth a total of £1.2 million. |
+4.2% |
Company filings. Not investment advice.